Welcome to the STING & TLR-Targeting Therapies Summit!
The 2nd STING- & TLR-Targeting Therapies Summit is dedicated to the development of drug candidates modulating the cGAS-STING and Toll-like receptor (3/7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches.
This forum comes at a critical point for the cancer immunotherapy field, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING, TLR plus other innate checkpoint inhibitors has been hugely promising.
This is the only industry-led forum dedicated to the safe and effective clinical and commercial translation of this class of cancer therapeutics. If you are a research team striving to accelerate the approval of innate immunity drug candidates, this is the specific networking forum which has been curated with you in mind.
View the Event Guide here to see the full agenda!
This virtual forum is designed so you interact with key clinical leaders from Checkmate Pharma, GSK, Bolt Biotherapeutics, Mersana Therapeutics, AstraZeneca and more, to discuss:
How to optimize the systematic and intratumoral administration of these agonists to lift innate immune barriers to anti-tumor immunity
How to initiate robust, localised response in the tumor microenvironment (TME) and address resistance to T-cell-based immunotherapies
Various therapeutic modalities including combinatorial approaches with PD-1/PD-L1 inhibitors, STING/TLR-agonist Antibody-Drug Conjugates and mRNA technologies
You will also have the opportunity to ask any burning questions and go back to your teams with a full picture of the innate immunotherapy pipeline and optimize your own research investments.
Innate Immune Checkpoints & Activation Pre-Focus Day
In addition to two full conference days to STING/TLR-targeting, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells, macrophages and myeloid-derived suppressor cells.
An executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system.
Pre-Focus Day Speakers Include:
If your research team is striving to harness the innate immune components of the TME to play a pivotal role in the activation and modulation of the adaptive immune response against the tumor, then this is the critical online networking forum for you in 2021.